Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

Bolus vaccines are often administered multiple times due to rapid clearance and reduced
transportation to draining lymph nodes resulting in inadequate activation of T and B …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

Background Addition of the BCL2 inhibitor venetoclax to lower intensity therapy has been
shown to improve overall survival in older (aged 75 years or older) and unfit patients with …

Despite the considerable efficacy observed when targeting a dispensable lineage antigen,
such as CD19 in B cell acute lymphoblastic leukaemia,, the broader applicability of adoptive …

Background Paediatric acute myeloid leukaemia (AML) is characterized by poor outcomes
in patients with relapsed/refractory disease, despite the improvements in intensive standard …

The bone marrow (BM) microenvironment regulates acute myeloid leukemia (AML) initiation,
proliferation, and chemotherapy resistance. Following cancer cell death, a growing body of …

Multi‐agent induction chemotherapy (IC) improves response rates in younger patients with
acute myeloid leukemia (AML); however, relapse remains the principal cause of treatment …

TET2 is recurrently mutated in acute myeloid leukemia (AML) and its deficiency promotes
leukemogenesis (driven by aggressive oncogenic mutations) and enhances leukemia stem …

Background Although the development of BCR:: ABL1 tyrosine kinase inhibitors (TKIs)
rendered chronic myeloid leukemia (CML) a manageable condition, acquisition of drug …